At a glance
- Originator Pfizer
- Class Respiratory stimulants
- Mechanism of Action Antioxidants; Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 04 Sep 2006 Discontinued - Preclinical for Chronic obstructive pulmonary disease in Italy (unspecified route)
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
- 05 Apr 2000 Monsanto has merged with Pharmacia & Upjohn to form Pharmacia Corporation